SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-108751
Filing Date
2020-04-16
Accepted
2020-04-16 08:49:03
Documents
4
Period of Report
2020-04-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d896317d8k.htm 8-K 46026
2 EX-1.1 d896317dex11.htm EX-1.1 190106
3 EX-5.1 d896317dex51.htm EX-5.1 12526
4 GRAPHIC g896317g0415115846721.jpg GRAPHIC 6987
  Complete submission text file 0001193125-20-108751.txt   259741
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 20795279
SIC: 2834 Pharmaceutical Preparations